Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies.

ABSTRACT:

SUBMITTER: Rogers KA 

PROVIDER: S-EPMC7425823 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature